1187932-64-4 Usage
Uses
Used in Pharmaceutical Synthesis:
Tert-butyl 7-bromo-3,4-dihydroquinoline-1(2H)-carboxylate is used as a building block for the synthesis of pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, tert-butyl 7-bromo-3,4-dihydroquinoline-1(2H)-carboxylate serves as a key component in the synthesis of various agrochemicals. Its incorporation into these products can enhance their effectiveness in agricultural applications.
Used as a Reagent in Organic Chemistry:
Due to its interesting properties and structure, tert-butyl 7-bromo-3,4-dihydroquinoline-1(2H)-carboxylate is also used as a reagent in organic chemistry reactions. It aids in the synthesis of complex organic compounds and contributes to the advancement of organic chemistry research.
Used in the Development of New Materials:
The potential applications of tert-butyl 7-bromo-3,4-dihydroquinoline-1(2H)-carboxylate extend beyond pharmaceuticals and agrochemicals. Its unique properties and structure make it a promising candidate for the development of new materials with diverse applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1187932-64-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,7,9,3 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1187932-64:
(9*1)+(8*1)+(7*8)+(6*7)+(5*9)+(4*3)+(3*2)+(2*6)+(1*4)=194
194 % 10 = 4
So 1187932-64-4 is a valid CAS Registry Number.
1187932-64-4Relevant academic research and scientific papers
Structure-guided rescaffolding of selective antagonists of BCL-X L
Koehler, Michael F. T.,Bergeron, Philippe,Choo, Edna F.,Lau, Kevin,Ndubaku, Chudi,Dudley, Danette,Gibbons, Paul,Sleebs, Brad E.,Rye, Carl S.,Nikolakopoulos, George,Bui, Chinh,Kulasegaram, Sanji,Kersten, Wilhelmus J. A.,Smith, Brian J.,Czabotar, Peter E.,Colman, Peter M.,Huang, David C. S.,Baell, Jonathan B.,Watson, Keith G.,Hasvold, Lisa,Tao, Zhi-Fu,Wang, Le,Souers, Andrew J.,Elmore, Steven W.,Flygare, John A.,Fairbrother, Wayne J.,Lessene, Guillaume
supporting information, p. 662 - 667 (2014/07/07)
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BC
